MicroRNA-363 inhibits ovarian cancer progression by inhibiting NOB1

Yang Lin; Tianmin Xu; Shunqing Zhou; Manhua Cui

doi:10.18632/oncotarget.21417

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

This article has been retracted. Retraction in: Oncotarget. 2023; 14:579-579.

MicroRNA-363 inhibits ovarian cancer progression by inhibiting NOB1

Yang Lin, Tianmin Xu, Shunqing Zhou and Manhua Cui _

PDF | HTML | How to cite

Oncotarget. 2017; 8:101649-101658. https://doi.org/10.18632/oncotarget.21417

Metrics: PDF 1301 views | HTML 2245 views | ?

Abstract

Yang Lin1, Tianmin Xu1, Shunqing Zhou1 and Manhua Cui1

1Department of Obstetrics and Gynecology, The Second Hospital, Jilin University, Nanguan District, Changchun 130041, China

Correspondence to:

Manhua Cui, email: [email protected]

Keywords: microRNAs; miR-363; ovarian cancer; NOB1

Received: May 11, 2017 Accepted: September 04, 2017 Published: September 30, 2017

ABSTRACT

In this study, we investigated the role of microRNA-363(miR-363) in ovarian cancer (OC) progression. MiR-363expression was downregulated in OC patient tissues and four OC cell lines (SKOV3, A2780, OVCAR and HO-8910). Low miR-363 levels were associated with advanced stage, lymph node metastasis, and poor prognosis in OC. MiR-363 overexpression decreased growth, colony formation, migration and invasiveness of SKOV3 cells. In addition, miR-363 overexpression in SKOV3 cells also decreased xenograft tumor size and weight in nude mice. Bioinformatics and dual luciferase reporter assays revealed that miR-363 suppresses expression of NIN1/RPN12 binding protein 1 homolog (NOB1) by binding to the 3’-UTR of its transcript. NOB1 expression inversely correlated with miR-363 levels in OC tissues. Thus miR-363 appears to play a tumor suppressor role in OC by inhibiting NOB1.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 21417

Publication Alerts

Research Papers:

MicroRNA-363 inhibits ovarian cancer progression by inhibiting NOB1

Abstract